ARKG
ETF Genomics NYSEARCA

ARK Genomic Revolution ETF

$27.09
+0.67 (+2.54%)
Fund Overview by ARK Invest

Actively managed fund focused on the genomic revolution: gene editing (CRISPR), molecular diagnostics, targeted therapeutics, stem cells, and agricultural biology. High-conviction positions in companies reshaping medicine.

AUM$1.8B
Expense Ratio0.75%
Holdings35
Dividend Yield0.0%
DistributionAnnually
BenchmarkNone (Active)
InceptionOct 2014
ExchangeNYSEARCA
Price Data
Open$26.78
Prev Close$26.42
Day Range$26.78 — $27.59
52W Range$17.55 — $34.37
52-Week Range
$17.55 $34.37
From 52W High
-21.2%
From 52W Low
+54.4%
Genomics ETF Comparison
ETF Price Change Expense AUM Holdings Yield
ARKG
ARK Genomic Revolution ETF
 $27.09 +2.54% 0.75% $1.8B 35 0.0%
IBB
iShares Biotechnology ETF
 $170.13 +0.76% 0.44% $7.8B 224 0.2%
XBI
SPDR S&P Biotech ETF
 $128.55 +0.64% 0.35% $6.5B 145 0.1%
Top Genomics Stocks View all →
Stock Price Change Market Cap
ABBV
Abbvie Inc
 $206.69 -1.03% 369.26B
AMGN
Amgen Inc
 $342.57 -1.54% 190.40B
GILD
Gilead Sciences Inc
 $140.13 +0.30% 166.66B
VRTX
Vertex Pharmaceuticals Inc
 $434.30 -1.01% 114.87B
REGN
Regeneron Pharmaceuticals
 $763.04 +0.16% 80.50B
ALNY
Alnylam Pharmaceuticals Inc
 $330.34 +3.60% 42.29B
INSM
Insmed Inc
 $163.81 +0.85% 35.01B
NTRA
Natera Inc
 $204.87 -1.50% 29.48B
BIIB
Biogen Inc
 $172.34 -2.82% 26.03B
UTHR
United Therapeutics Corp
 $559.65 -0.91% 24.75B
ARKG FAQ
What is ARKG?
ARKG is the ARK Genomic Revolution ETF, an exchange-traded fund managed by ARK Invest. It tracks the None (Active) and holds 35 Genomics securities with an expense ratio of 0.75%.
What is the expense ratio of ARKG?
ARKG charges an annual expense ratio of 0.75%, which means you pay $75.00 per year for every $10,000 invested. This fee is deducted automatically from the fund's returns.
What are the alternatives to ARKG?
Other genomics ETFs include IBB, XBI. Each offers different expense ratios, weighting methodologies, and number of holdings. Compare them in the ETF comparison table above to find the best fit for your portfolio.
Explore Genomics Stocks
View our full list of individual genomics stocks with prices, fundamentals, and analyst ratings.
View List →

Last updated: Apr 1, 2026 at 10:14 PM ET